FindTrial
Sign In

the effect of HBV RNA in evaluating hepatitis B reactivation in tumor- patients with HBsAg negative/anti-HBC positive

the effect of HBV RNA in evaluating hepatitis B reactivation in tumor- patients with HBsAg negative/anti-HBC positive

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064202
Enrollment
Unknown
Registered
2022-09-30
Start date
2022-09-30
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumor-patients with HBsAg-negative/anti-HBc positive

Interventions

NAs-treated group:NAs
control group:No NAs

Sponsors

General Hospital of Eastern Theater Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: patients with tumor;HBsAg negative/anti-HBC positive ; have no necleotides before anti-tumor treatment

Exclusion criteria

Exclusion criteria: already have necleotides before anti-tumor treatment;already have anti-tumor treatment before study; combined with other disease;have other causes of abnormal liver function

Design outcomes

Primary

MeasureTime frame
positive;positive or increased;—

Countries

China

Contacts

Public ContactYuecheng YU

General Hospital of Eastern Theate Command

gslsycy@163.com+86 13805168619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026